Welcome to our dedicated page for Nautilus Biotechnolgy news (Ticker: NAUT), a resource for investors and traders seeking the latest updates and insights on Nautilus Biotechnolgy stock.
Nautilus Biotechnology, Inc., trading under the symbol NAUT, is a pioneering life sciences company based in Seattle, Washington, with research and development headquarters in San Carlos, California. The company is on a mission to revolutionize the field of proteomics by creating a platform technology designed to quantify and unlock the complexities of the human proteome. With this innovation, Nautilus aims to accelerate therapeutic development, enhance medical diagnostics, and promote personalized and predictive medicine.
The company’s core innovation is the Proteomic Analysis System, a single-molecule instrument prototype that offers unprecedented insights into the proteome. Nautilus brings together an extraordinary team of experts from diverse disciplines, including protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, and bioinformaticists. This multidisciplinary approach positions Nautilus to spearhead major advancements in drug development and human health management.
Nautilus has demonstrated significant progress in recent quarters, as highlighted by CEO Sujal Patel in their latest press release. Patel expressed excitement over the company's Q2 achievements, including the ability to integrate multiple platform elements such as sample preparation, affinity reagent probes, chips, flow cells, the instrument, multi-cycle assay, and software into a cohesive system. This development marks an essential step towards their commercial launch scheduled for next year.
Despite these ambitious projects, Nautilus maintains sound fiscal discipline, ensuring financial stability that extends operational funding through 2025 and into 2026. The company uses various channels to disclose material non-public information, including filings with the Securities and Exchange Commission, its website, press releases, public conference calls, public webcasts, and social media accounts.
Notably, Dr. Parag Mallick, a key visionary at Nautilus, was recently honored with the Computational Proteomics Award from US HUPO for his groundbreaking contributions to the field. Dr. Mallick's work in bioinformatics and computational methods has been instrumental in advancing proteomics research globally.
For investors and stakeholders keen on tracking the company's developments, Nautilus provides regular updates on their website and through investor relations contacts. To learn more about Nautilus Biotechnology, their mission, and their cutting-edge work in proteomics, visit their official website at www.nautilus.bio.
Nautilus Biotechnology (NASDAQ: NAUT) announced that its co-founder and Chief Scientist, Parag Mallick, Ph.D., has been awarded the 2024 Distinguished Investigator Award by the Academy for Radiology and Biomedical Imaging Research. The award recognizes Dr. Mallick's significant contributions to imaging research, including his leadership, high-impact publications, and ongoing research and development work. Dr. Mallick will be inducted into the Academy's Council of Distinguished Investigators during the Annual Meeting of the Radiological Society of North America in December 2024.
Nautilus Biotechnology (NASDAQ: NAUT), a pioneer in single-molecule protein analysis platforms, has announced its participation in the Inaugural Guggenheim Healthcare Conference. The company's management will engage in a fireside chat on Wednesday, November 13, 2024, at 9:30 a.m. Eastern Time. The presentation will be accessible via live and archived webcast through the 'Investors' section of www.nautilus.bio.
Nautilus Biotechnology (NASDAQ: NAUT) reported its Q3 2024 financial results. The company, which focuses on single-molecule proteome analysis platform development, recorded operating expenses of $19.1 million, unchanged from the previous year. The net loss increased to $16.4 million compared to $15.9 million in Q3 2023. As of September 30, 2024, the company maintained a strong financial position with $221.2 million in cash, cash equivalents, and investments.
Nautilus Biotechnology (NASDAQ: NAUT), a pioneer in single molecule protein analysis platforms, has announced it will release its third quarter 2024 financial results on Tuesday, October 29, 2024, before the market opens. The company's management will host a conference call and webcast at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time on the same day to discuss the results, business developments, and future outlook.
Interested parties can access the live audio webcast of the conference call through the 'Investors' section of Nautilus Biotechnology's official website at www.nautilus.bio. This event provides an opportunity for stakeholders and investors to gain insights into the company's financial performance and strategic direction.
Nautilus Biotechnology (NASDAQ: NAUT) has appointed Ken Suzuki as Chief Marketing Officer. Suzuki, a 25-year veteran from Agilent Technologies, brings extensive experience in mass spectrometry and proteomics to Nautilus, a company developing a single-molecule protein analysis platform. This strategic hire comes as Nautilus prepares to launch its Proteome Analysis Platform.
Suzuki's background includes leadership roles in Agilent's Mass Spectrometry division, Strategic Program Office, and Spectroscopy department. His expertise spans marketing, product development, finance, and R&D in the life sciences sector. Nautilus CEO Sujal Patel expressed enthusiasm about Suzuki's potential impact on bringing the company's platform to researchers worldwide.
Nautilus Biotechnology (NASDAQ: NAUT), a pioneer in single-molecule proteome analysis, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York. The company's management will engage in a fireside chat on September 4, 2024, at 7:00 a.m. Eastern Time.
This event presents an opportunity for investors and interested parties to gain insights into Nautilus's innovative proteomics platform. A live and archived webcast of the presentation will be accessible through the 'Investors' section of the company's website at www.nautilus.bio, allowing for widespread access to the discussion.
Nautilus Biotechnology (NASDAQ: NAUT) reported its Q2 2024 financial results, showcasing progress in its single-molecule proteome analysis platform development. Operating expenses increased 9% to $20.8 million, primarily due to headcount growth. The company reported a net loss of $18.0 million, up from $15.8 million in the same period last year. As of June 30, 2024, Nautilus maintained a strong financial position with $232.9 million in cash, cash equivalents, and investments. CEO Sujal Patel emphasized the company's pioneering approach to overcome limitations in traditional protein analysis methods, focusing on both targeted proteoform analysis and broadscale discovery in proteomics.
Nautilus Biotechnology (NASDAQ: NAUT) has announced it will release its second quarter 2024 financial results on July 30, 2024, before the market opens. The company will host a webcast conference call at 5:30 a.m. PT / 8:30 a.m. ET to discuss the results, recent business developments, and future outlook. Interested parties can access the live audio webcast via the 'Investors' section of Nautilus' website at www.nautilus.bio.
Nautilus Biotechnology, a leader in single-molecule protein analysis, will join the Goldman Sachs 45th Annual Global Healthcare Conference. The event is set for June 10, 2024, at 8:40 a.m. ET. Nautilus' management will participate in a fireside chat, which will be available via live and archived webcast on their investor relations page.
Nautilus Biotechnology, Inc. reported its financial results for the first quarter of 2024, showing positive progress against core development goals. Operating expenses increased by 20% due to higher headcount for product development. Despite a net loss of $18.7 million, the company maintains a strong financial position with $247.7 million in cash, cash equivalents, and investments.
FAQ
What is the current stock price of Nautilus Biotechnolgy (NAUT)?
What is the market cap of Nautilus Biotechnolgy (NAUT)?
What is Nautilus Biotechnology, Inc.?
What is the core technology developed by Nautilus Biotechnology?
Where is Nautilus Biotechnology headquartered?
What are the recent achievements of Nautilus Biotechnology?
Who is the CEO of Nautilus Biotechnology?
When will Nautilus's new platform be commercially launched?
How does Nautilus disclose important information?
Who was recently honored with the Computational Proteomics Award?
What is Nautilus's financial outlook?
Where can I find more information about Nautilus Biotechnology?
